Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cytochrome P450 family 3 subfamily A member 43 (CYP3A43)
- Target
- CYP3A43
- Molecular classification
- Enzyme, Cytochrome P450, Monooxygenase
01
Overview
Cytochrome P450 family 3 subfamily A member 43 (CYP3A43) is a heme-thiolate monooxygenase found primarily in the liver but also expressed in a variety of tissues. As a member of the CYP3A subfamily, it shares homology with CYP3A4, CYP3A5, and CYP3A7, but exhibits distinct substrate specificities and lower monooxygenase activity levels, notably for testosterone and estrogen metabolism. CYP3A43 is implicated in steroid synthesis, drug metabolism, and may have roles in cancer progression, particularly prostate cancer. Its clinical relevance is underscored by its genetic variability (alternative splicing, polymorphisms) and potential contribution to inter-individual differences in drug response and disease risk.
- Other names
- Cytochrome P450 3A43CYP3A43cytochrome P450, family 3, subfamily A, polypeptide 43cytochrome P450, subfamily IIIA, polypeptide 43
02
Mechanism of action
Monooxygenation of substrates (oxidation through heme iron) Hydroxylation (e.g., 6-beta-hydroxylation of testosterone, 16-alpha-hydroxylation of estrogen)
03
Biological functions
Drug metabolism (monooxygenase activity)Synthesis of cholesterol, steroids, and other lipidsHormone biosynthesis (testosterone and estrogen metabolism, low testosterone 6-beta-hydroxylase activity, estrogen 16-alpha-hydroxylase activity)Possibly aging mechanisms and cancer progression
04
Disease associations
Cancer (notably prostate cancer)Other (potential roles in aging and other metabolic processes)
05
Safety considerations
Drug-drug interactions (if co-administered drugs are metabolized by CYP3A43 or if polymorphisms alter activity)Adverse drug reactions due to metabolic variabilityGenetic variability (alternative splicing and polymorphisms may alter enzyme activity)
06
Interacting drugs
Potential interactions with drugs metabolized by cytochrome P450 family 3A enzymes (e.g., testosterone, clomipramine, possibly overlapping substrate specificity with CYP3A4/5/7, but specific clinical data for CYP3A43 is limited)
07
Biomarkers
Possible for prostate cancer and pharmacogenetics (further clinical validation required; not broadly established)
Beyond the preview
Go deeper on Cytochrome P450 family 3 subfamily A member 43 (CYP3A43).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cytochrome P450 family 3 subfamily A member 43 (CYP3A43).